Ascensia touts interconnected approach to diabetes care

 - 
Tuesday, June 11, 2019

SAN FRANCISCO – People with Type 2 diabetes who participated in a pilot study using Ascensia Diabetes Care’s investigational Interconnected Diabetes Management Solution significantly lowered HbA1c, the company reported at the American Diabetes Association’s 79th Scientific Sessions in June.  As the primary endpoint, mean HbA1c decreased by 0.43%, from 8.44% at the start to 8.01% after 12 weeks. “These data are the first indication of clinically meaningful results from the use of this IDMS and suggest that the solution has the potential for benefit in the management of Type 2 diabetes,” the company said. Ascensia’s investigational solution is designed to provide additional support for adults with diabetes to help them more effectively manage their condition. It uses a combination of remote behavioral coaching from a Certified Diabetes Educator and a mobile application. The CDE is able to use the person’s data to customize their coaching  guidance, providing them with actionable information to support individual self-management.